Oxytocin and eating disorders: Knowledge gaps and future directions

Russell, Janice; Hunt, Glenn E.

doi:10.1016/j.psyneuen.2023.106290

Cited by 3 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another PEG-ylated NMU analog and selective NMUR2 agonist, named Compound 37 manifested a strong, dose-dependent anorexigenic effect in mice: with a weight loss of more than 12% in two weeks (Kanematsu-Yamaki et al, 2017). Intranasally delivered oxytocin did not meet its therapeutic expectations in the treatment of obesity and eating disorders (McCormack et al, 2023;Russell & Hunt, 2023). Given all the aforementioned data, an administration of NMURs agonists seems to be a promising and safe alternative for the treatment of obesity and other metabolic disturbances with oxytocin or leptin.…”

Section: Effec T Of Nmur 2 Ag Onis Ts On E Ating B Ehavi or And Energ...mentioning

confidence: 99%

Pharmacomodulation of brain neuromedin U signaling as a potential therapeutic strategy

Pałasz

Worthington

Filipczyk

et al. 2023

J of Neuroscience Research

View full text Add to dashboard Cite

Neuromedin U (NMU) belongs to a family of multifunctional neuropeptides that modulate the activity of several neural networks of the brain. Acting via metabotropic receptor NMUR2, NMU plays a role in the regulation of multiple systems, including energy homeostasis, stress responses, circadian rhythms, and endocrine signaling. The involvement of NMU signaling in the central regulation of important neurophysiological processes and its disturbances is a potential target for pharmacological modulation. Number of preclinical studies have proven that both modified NMU analogues such as PASR8‐NMU or F4R8‐NMU and designed NMUR2 agonists, for example, CPN‐116, CPN‐124 exhibit a distinct pharmacological activity especially when delivered transnasally. Their application can potentially be useful in the more convenient and safe treatment of obesity, eating disorders, Alzheimer's disease‐related memory impairment, alcohol addiction, and sleep disturbances. Accumulating findings suggest that pharmacomodulation of the central NMU signaling may be a promising strategy in the treatment of several neuropsychiatric disorders.

show abstract

Section: Effec T Of Nmur 2 Ag Onis Ts On E Ating B Ehavi or And Energ...mentioning

confidence: 99%